Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst rati

GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its

FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late

https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adult

GSK announced today that Health Canada has approved Exdensur (depemokimab) for two indications:As an

During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst

GSK plc (LSE/NYSE:GSK) today announced that momelotinib, a JAK inhibitor with a differentiated mecha

The Nasdaq 100 sank 3.3% Tuesday as AI and optical stocks cratered, while cash rotated into real est

GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares su

Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/o

In times of market turbulence, investors turn to dividend-yielding stocks. Benzinga provides real-ti

GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while la

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook

https://www.gov.uk/government/news/mhra-approves-linerixibat-lynavoy-for-the-treatment-of-itch-due-t

Sen. Warren challenges Trump's 600% TrumpRx drug price claim using a glass of water.

GSK Q1 earnings beat expectations with $10.22B in sales, driven by strong Shingrix vaccine demand. S

2026 guidance and 2031 sales outlook reaffirmed • Expect 2026 turnover growth of between 3% to 5%; C

GSK (NYSE:GSK) reported quarterly earnings of $1.25 per share which beat the analyst consensus estim

AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the la

https://www.gsk.com/en-gb/media/press-releases/gsk-s-investigational-liver-therapy-efimosfermin-rece

https://www.alfasigma.com/wp-content/uploads/2026/04/Alfasigma-Completes-Agreement-with-GSK-for-line

Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty r

FDA court freeze leaves COVID, flu, RSV vaccines in limbo as Kennedy's ACIP overhaul faces legal

https://www.londonstockexchange.com/news-article/GSK/blenrep-approved-in-china-for-2l-multiple-myelo

GSK sees blockbuster potential for Mo-Rez after early trial data shows strong tumor reduction in har

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermati

According to a Bloomberg report, Trump may impose 100% tariffs on drugmakers without pricing deals,

https://www.shionogi.com/global/en/news/2026/04/20260401_12.html

https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-in-china-for-the-treatm

AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock R

Submission supported by statistically significant and clinically meaningful functional cure rates in

Wave Life Sciences stock drops after INLIGHT Phase 1 data. WVE-007 shows fat reduction, lean mass st

https://www.gsk.com/en-gb/media/press-releases/gsk-s-b7-h3-targeted-antibody-drug-conjugate-risvutat

Medicare Chief Chris Klomp is optimistic for strong outcome in the search of CDC leader in midst of

A federal judge warns that RFK Jr.'s vaccine overhaul likely violates federal law. Discover the

Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership w

FDA expands GSK's Arexvy RSV vaccine approval to high-risk adults aged 18–49, widening access be

GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has expanded t

FDA approves expanded use of Wellcovorin tablets to treat cerebral folate deficiency linked to the F

Submission supported by statistically significant and clinically meaningful functional cure rates de

Submission based on data from positive GLISTEN phase III trialLinerixibat demonstrated significant a

GSK will acquire 35Pharma for $950 million, adding HS235, a new drug candidate targeting pulmonary h

Frontier Biotechnologies Inc. (hereinafter referred to as "Frontier Biotech" or "the Com

Merck reports positive RSV trial data, eyes expanded FDA use in children as shares trade near 52-wee

EU approves GSK's Exdensur for severe asthma and nasal polyps, offering twice-yearly dosing and